- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,160GBP
- Report
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,156GBP
- Report
- October 2022
- 270 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- November 2023
- 115 Pages
United States
From €3413EUR$3,750USD£2,899GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,126GBP
- Report
- April 2018
United States
From €7277EUR$7,995USD£6,181GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$4,119USD£3,077GBP

Abatacept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It works by blocking the activity of a molecule called CTLA-4, which is involved in the body's immune response. Abatacept is administered through an intravenous infusion or subcutaneous injection. It is used to reduce inflammation and pain associated with these conditions, as well as to slow down the progression of joint damage.
Abatacept is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is one of several biologic drugs used to treat immune disorders, and is often used in combination with other medications.
Some companies in the Abatacept market include Bristol-Myers Squibb, AstraZeneca, and Pfizer. Show Less Read more